Study of Intracoronary CD34+ Cell Administration in Patients With Early Coronary Atherosclerosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03471611
Recruitment Status : Recruiting
First Posted : March 20, 2018
Last Update Posted : October 23, 2018
Information provided by (Responsible Party):
Amir Lerman, Mayo Clinic

Brief Summary:
How safe and effective are CD34+ cell intracoronary injections for treating coronary endothelial dysfunction (CED)?

Condition or disease Intervention/treatment Phase
Atherosclerosis, Coronary Drug: Autologous CD34+ Cells Drug: Granulocyte Colony-Stimulating Factor (G-CSF) Phase 1

Detailed Description:
This is an open label, phase I study to determine safety and efficacy of CD34+ cells in the treatment and management of CED and early atherosclerosis. Coronary endothelial function will be assessed in all patients by the administration of intracoronary acetylcholine. Patients with endothelial dysfunction who meet study inclusion criteria will receive granulocyte cell stimulating factor (G-CSF), followed by apheresis. The mobilized peripheral cell product will be processed for selection of CD34+ stem cells, and the purified CD34+ cells will be administered intracoronary during cardiac catheterization. The patients will undergo repeat endothelial function assessment 6 months post-procedure, as well as clinical assessments as described below either via in-person assessment by a nurse or physician, or via phone-call using a standardized questionnaire at 1, 3, and 6 month follow-up visits. At one month, the patient will undergo basic laboratory testing including troponin levels, complete blood count (CBC), electrolyte panel, liver function testing and ECG. At 3 months, the patients will receive a phone follow-up by the study coordinator who will assess the patient for any clinical deterioration or significant worsening in symptoms. At 6 months, the patients will return for a clinical visit, which will include physical examination, basic laboratory testing and follow-up acetylcholine study with angiography to assess for change in endothelial function. The first three patients will be sequentially enrolled, and subsequent enrollment will be held until one month follow-up. Provided there are no safety concerns at this time, enrollment will continue.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1, Feasibility Study Testing the Safety and Feasibility of Intracoronary CD34+ Cell Administration on Coronary Endothelial Function in Patients With Early Coronary Atherosclerosis
Actual Study Start Date : June 15, 2018
Estimated Primary Completion Date : May 1, 2022
Estimated Study Completion Date : May 1, 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Atherosclerosis

Arm Intervention/treatment
Experimental: Subjects with Endothelial Dysfunction
Subjects will be treated with Granulocyte Colony-Stimulating Factor (G-CSF) for 5 days at a dose of 5 mg/kg twice daily. When count of CD34+ cells is sufficient, the CD34+ cells will be collected by apheresis. Autologous CD34+ cells will be injected into the subjects at a rate of 10 ml/min.
Drug: Autologous CD34+ Cells
The dose will be 1x10^5 cells/kg, injected at the rate of 10 ml/min

Drug: Granulocyte Colony-Stimulating Factor (G-CSF)
5mg/kg twice daily
Other Names:
  • Neupogen
  • Neulasta

Primary Outcome Measures :
  1. Number of subjects experiencing adverse events [ Time Frame: 12 months ]
  2. Number of subjects experiencing serious adverse events [ Time Frame: 12 months ]
  3. Number of subjects experiencing Major Adverse Cardiovascular Events (MACE) [ Time Frame: 12 months ]
    The most commonly reported major cardiovascular adverse events (MACE) include myocardial infarction, heart failure, percutaneous cardiac intervention, coronary artery bypass grafting, malignant dysrhythmia, cardiac shock, implantable cardiac defibrillator, malignant dysrhythmia and death.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosis of coronary endothelial dysfunction based on coronary angiogram and acetylcholine comprehensive coronary physiology study
  • Able to provide informed written consent and willing to participate in all required study follow-up assessments

Exclusion Criteria:

  • Acute coronary syndrome or continuous/ongoing chest pain - unremitting and unresponsive to nitroglycerin or rest - persisting 4 or more days before stent placement. If the chest pain syndrome is transient and/or intermittent - even if it began more than 3 days prior to admission - the patient is not excluded.
  • Subjects in cardiogenic shock (systolic pressure < 80mm/Hg, on vasopressors or intraaortic counter pulsation) at the time of consenting. Subjects who recover from cardiogenic shock by the time of consenting are eligible.
  • Subjects unable to receive antiplatelet agents (e.g. aspirin, clopidogrel, ticlopidine,prasugrel, etc).
  • Abnormal laboratory values (Hgb <11 mg/dL; glomerular filtration rate (GFR)<50; liver function tests (LFTs)>2x upper limit of normal).
  • Subjects receiving warfarin who have an international normalized ratio (INR) >2 at the end of the screening phase or with major bleeding requiring active transfusion support.
  • Subjects with severe cardiac valvular disease expected to undergo surgery within 1 year.
  • Subjects with known severe immunodeficiency states (AIDS).
  • Significant coronary artery disease on coronary angiogram
  • Cirrhosis requiring active medical management.
  • Malignancy requiring active treatment (except basal cell skin cancer).
  • Subjects with documented active alcohol and /or other substance abuse.
  • Females of child bearing potential unless a pregnancy test is negative within 7 days of the bone marrow harvest.
  • Re-occlusion of the infarct related artery (IRA) prior to the infusion procedure.
  • Planned revascularization intervention during the next 6 months. (A second PCI can be performed if done prior to qualifying cardiovascular magnetic resonance imaging (CMR) at least 96 hours post primary PCI).
  • Participation in an ongoing investigational trial.
  • Active or suspected bacterial infection requiring systemic intravenous antibiotics.
  • Additional factors deemed unsuitable for trial enrollment per discretion of principal investigator
  • Inmates

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03471611

Contact: Diana P Albers, BS 507-255-6884

United States, Minnesota
Mayo Clinic in Rochester Recruiting
Rochester, Minnesota, United States, 55905
Contact: Diana P Albers, BS    507-255-6884   
Principal Investigator: Amir Lerman, MD         
Sponsors and Collaborators
Mayo Clinic
Principal Investigator: Amir Lerman Mayo Clinic

Responsible Party: Amir Lerman, Principal Investigator, Mayo Clinic Identifier: NCT03471611     History of Changes
Other Study ID Numbers: 17-005743
First Posted: March 20, 2018    Key Record Dates
Last Update Posted: October 23, 2018
Last Verified: October 2018

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Coronary Artery Disease
Myocardial Ischemia
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases
Coronary Disease
Heart Diseases
Adjuvants, Immunologic
Immunologic Factors
Physiological Effects of Drugs